艾迪注射液对非小细胞肺癌化疗患者的辅助疗效分析

Analysis of Adjuvant Effect of Aidi Injection on Chemotherapy Patients with Non-Small Cell Lung Cancer

目的探讨观察艾迪注射液辅助化疗对非小细胞肺癌患者的临床治疗效果。方法选取2013年1月—2017年12月收治于该院并确诊为非小细胞肺癌的患者共77例作为研究对象,根据随机的原则,将他们分为对照组与观察组,其中对照组43例,患者治疗时采用单纯化疗的方式;观察组34例,患者治疗时在化疗的基础上进行艾迪注射液的辅助治疗,最后统计分析两组患者疾病的治疗有效率及白细胞和/或血小板减少的发生率。并对所得数据进行回顾性分析。结果在进行单纯化疗的43例对照组患者中,完全缓解的患者有10例,占比23.25%(10/43),部分缓解的患者有20例,占比46.51%(20/43),总的治疗有效率为69.77%(30/43),发生白细胞和/或血小板减少的患者有20例,占比46.51%(20/43);经艾迪注射液辅助化疗的34例观察组患者中,完全缓解的患者有12例,占比35.29%(12/34),部分缓解的患者有16例,占比47.06%(16/34),总的治疗有效率为82.35%(28/34),发生白细胞和/或血小板减少的患者有10例,占比29.41%(10/34)。观察组患者的疾病治疗有效率显著高于对照组,且发生白细胞和/或血小板减少的概率显著下降。两组数据之间差异有统计学意义(χ~2=8.364,P<0.05)。结论临床实践中,在对非小细胞肺癌患者进行化疗时,建议在化疗的基础上进行艾迪注射液的辅助治疗,有利于提高患者的疾病治疗有效率及降低白细胞和/或血小板减少的发生率,提高患者的生命质量,值得在临床上进一步推广。

Objective To investigate the clinical effect of adjuvant chemotherapy with Aidi injection on patients with no,l-small cell lung cancer. Methods A total of 77 patients who were admitted to the hospital from January 2013 to December 2017 and diagnosed as non-small cell lung cancer were enrolled. According to the principle of randomiza- tion, they were divided into control group and observation group. Forty-three patients were treated with chemotherapy alone. In the observation group, 34 patients were treated with Aidi injection on the basis of chemotherapy. Finally, the effective treatment of disease in both groups and white blood cells and/or the incidence of thrombocytopenia. The data were retrospectively analyzed. Results Of the 43 control patients who underwent chemotherapy alone, 10 had complete remission, accounting for 23.259o （10/43）, and 20 patients had partial remission, accounting for 46.519o （20/43）. The total effective rate was 69.77% （30/43）, 20 patients with leukopenia and / or thrombocytopenia, accounting for 46.51% （20/43）; 34 patients in the observation group treated with Aidi injection adjuvant chemotherapy among them, 12 pa- tients had complete remission, accounting for 35.29% （12/34）, 16 patients with partial remission, accounting for 47.06% （16/34）, and the total effective rate was 82.35% （28/34）. There were 10 patients with leukopenia and / or thrombocy- topenia, accounting for 29.41% （10/34）. Patients in the observation group were significantly more effective in treating diseases than in the control group, and the probability of leukopenia and/or thrombocytopenia was significantly reduced.There was a significant difference between the two groups of data and statistical significance （χ2=8.364, P〈0.05）. Con- elusion In clinical practice, in the chemotherapy of patients with non-small cell lung cancer, it is recommended to car- ry out adjuvant treatment of Aidi injection on the basis of chemotherapy, which is beneficial to improve the efficiency of disease treatment and reduce white blood cell and / or thrombocytopenia ilncidence, improve the quality of life of pa- tients, it is worth further clinical promotion.